Embracing the Change: Revisiting Simon-Kucher 2020 China NRDL Predictions
Published on January 19, 2023
China’s 2020 NRDL (National Reimbursement Drug List) results are out, marking many firsts in history. In this article, we revisit the three themes and five predictions from our NRDL perspectives last October, and cordially invite you for a quick survey on its future outlook.
China doesn’t take a break over Christmas, which works out well for the NHSA (National Health Security Administration). On December 28 2020, the NHSA released the much-awaited official results of the latest NRDL update.
As expected, the 2020 NRDL marked several firsts in history,
- For the very first time, there were around 700 drugs going into the process;
- Subsequently, 162 drugs made it into the shortlist, and 119 of them eventually made the listing, breaking the record for most inclusions in NRDL history;
- Of the new additions, 17 drugs were recently approved in China between January and August 2020, underscoring the NHSA’s increasing commitment…
